September 21, 2011

Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

August 18, 2011

With the global biosimilars market expected to expand nearly sixfold by the middle of the decade, market research firm IMS Health is launching a market-measurement tool for drug makers interested in getting into the space, the company said.

August 9, 2011

Profits for Endo Pharmaceutical Holdings rose to $54.6 million during second quarter 2011, up 6% from $51.5 million in second quarter 2010, the drug maker said.

August 3, 2011

Par Pharmaceutical had sales of $224.2 million and profits of $9.05 million during second quarter 2011, the drug maker said Wednesday.

May 26, 2011

Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.

May 18, 2011

Global spending on medicines will reach nearly $1.1 trillion by 2015, according to a new study by market research firm IMS Health.

May 17, 2011

A Food and Drug Administration panel will discuss findings in a clinical trial that has raised concerns about the safety and efficacy of Abbott's cholesterol-lowering drug when it’s combined with similar drugs, according to an FDA announcement.

April 18, 2011

A U.S. drug maker and its Japanese partner have started a late-stage clinical trial of a drug for treating elevated phosphate levels in the body, the two announced Monday.

April 6, 2011

The Center for Healthcare Supply Chain Research, the research foundation of the Healthcare Distribution Management Association, on Tuesday released “Assessing the Impact of Risk Evaluation and Mitigation Strategies (REMS) Requirements on the Pharmaceutical Supply Chain,” the first comprehensive research study analyzing the impact of REMS programs across the healthcare supply chain.

March 7, 2011

Late-stage clinical trial data for a Keryx Biopharmaceuticals drug to treat kidney disease will be presented at a medical conference in Las Vegas.

January 18, 2011

Healthcare market research firm IMS Health will buy privately held market research firm SDI Health, IMS said.

January 12, 2011

Drug maker Merck and drug industry services organization Parexel International will work together to develop biosimilars, the two said Wednesday.

November 9, 2010

Watson Pharmaceuticals biotech subsidiary Eden Biodesign has signed a manufacturing agreement with Dutch biotech company...

November 2, 2010

Earnings per share for AmerisourceBergen rose nearly 14% during the fourth quarter ended Sept. 30,...

October 7, 2010

Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C,...

August 18, 2010

A company that develops drugs for cardiovascular disease has appointed a new leader....

June 6, 2010

While consumers probably won’t feel the pain, the increasing complexity of clinical trials will make...

May 16, 2010

Pharmaceuticals are expected to become a global market worth more than $1 trillion within four...

March 24, 2010

Innovation is the way to improve quality and access to health care while controlling costs,...

February 28, 2010

Companies developing drugs to treat especially rare conditions may find winning regulatory approval in the...

February 23, 2010

The Food and Drug Administration and the National Institutes of Health hope to accelerate the...

February 16, 2010

Anglo-Swedish drug maker AstraZeneca and American drug maker Rigel Pharmaceuticals have signed a global licensing...

February 10, 2010

Traditional care delivery models will continue to give way to alternative care delivery models, such...

December 31, 2009

Stymied by weak demand in a recessionary economy, intensifying generic competition, a relative dearth of research-and-development breakthroughs and an ongoing loss of patent protection for some of their biggest-selling pioneering medicines, branded pharmaceutical manufacturers have scrambled over the last three years to restore their once-enviable track record for product innovation and sales growth. And 2009 was no exception.